Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies.

CAR T cells have demonstrated unique potency for tumor cytoreduction and durable response in hematological malignancies. However, disease relapse remains a concern due to the emergence of antigen negative variants, tolerization of CAR T cell populations and lack of T cell persistence. We postulated that vaccination with a personalized cancer vaccine, that we developed, in which patient derived tumor cells are fused with autologous dendritic cells would enhance CAR T cell efficacy through the expansion of T cell clonal populations and the vaccine mediated enhancement of T cell activation and persistence.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Marzia Capelletti, Jessica Liegel, Maria Themeli, Tuna Mutis, Dina Stroopinsky, Shira Orr, Daniela Torres, Adam Morin, Gertrude Gunset, Haider Ghiasuddin, Maryam Rahimian, Myrna R. Nahas, Lina Bisharat, Nikhil C. Munshi, Donald Kufe, Jacalyn Rosenblatt, M Tags: 54 Source Type: research